Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape
Australian & New Zealand Journal of Psychiatry – December 17, 2025
Source: OpenAlex
Summary
Australia's groundbreaking reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression marks a global first in psychedelic medicine policy. However, its implementation faces significant hurdles. Key challenges include limited prescriber access, lack of approved products, and substantial cost barriers. Ethical considerations, such as informed consent and cultural safety in trauma-informed care, are also critical. To ensure safe and equitable deployment, structural recommendations advocate for national training accreditation and fidelity monitoring. Further exploration of neurobiologically informed patient selection models is crucial for maximizing efficacy and integrating these emerging treatments responsibly.
Abstract
Australia’s reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities surrounding the provision of psilocybin-assisted therapy in clinical practice. Key issues include limited prescriber access, absence of Australian Register of Therapeutic Goods-listed products, lack of standardised training pathways and significant cost barriers. Ethical considerations such as informed consent, cultural safety and therapeutic fidelity are also discussed, particularly in the context of trauma-informed care. This article proposes a series of structural recommendations to support safe and equitable deployment, including national training accreditation and fidelity monitoring tools. In addition, to maximise the efficacy of psilocybin-assisted therapy, we recommend that research explores the potential of neurobiologically informed stratification models to assist with treatment recommendations. These recommendations aim to enhance clinical integrity through evidence-based patient selection, improved safety, and to ensure that emerging psychedelic treatments are integrated responsibly within Australia’s mental health system. By addressing these foundational gaps, Australia can move beyond regulatory novelty ensuring the therapeutic potential of these products is realised in a manner which is scientifically sound and upholds the integrity of psychiatric practice.